APS and APTOF Related Headlines
Go Back- Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
- Aptose reports positive results from AML drug trial at EHA congress
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Reports First Quarter 2026 Results
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
- Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
- Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
- Aptose Reports Third Quarter 2025 Results
- Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
APS and APTOF Related Press Releases
Go Back- Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
- Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Reports First Quarter 2026 Results
- Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
- Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement
- Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
- Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders
- Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC
- Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations
- Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
- Aptose Reports Third Quarter 2025 Results
- Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
APS and APTOF Related SEC Filings
Go Back- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Seizinger Bernd R.
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Whitehead Warren
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Vincent Mark D.
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Rice William G.
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: PLATZER ERICH
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Payne Fletcher
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: BURGER DENIS R
- Form 4 Aptose Biosciences Inc. For: Jun 30 Filed by: Bejar Rafael
- Form 15-12G Aptose Biosciences Inc.
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Jun 30
- Form 8-K Aptose Biosciences Inc. For: Jun 30
- Form 8-K Aptose Biosciences Inc. For: Jun 15
- Form 8-K Aptose Biosciences Inc. For: May 29
- Form 10-Q Aptose Biosciences Inc. For: Mar 31
- Form 8-K Aptose Biosciences Inc. For: May 13
- Form 8-K Aptose Biosciences Inc. For: Apr 30
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form 10-K Aptose Biosciences Inc. For: Dec 31
- Form 8-K Aptose Biosciences Inc. For: Mar 31
- Form 8-K Aptose Biosciences Inc. For: Mar 31
- Form RW Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Mar 12
- Form 8-K Aptose Biosciences Inc. For: Mar 23
- Form 8-K Aptose Biosciences Inc. For: Mar 19
- Form DEFM14A Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Feb 23
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form SC 13E3/A Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form PRER14A Aptose Biosciences Inc.
- Form SC 13E3 Aptose Biosciences Inc. Filed by: Aptose Biosciences Inc.
- Form 8-K Aptose Biosciences Inc. For: Dec 19
